Evidence map›Paper›PMID 22332908›Full record

Trial reportNutrition and cancer2012

Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer.

Weizhu Zhu, Wenyi Qin, Ke Zhang, George E Rottinghaus, Yin-Chieh Chen, Beth Kliethermes, Edward R Sauter

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrition and cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 1 synthesis or guideline pooled it, 229 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Weizhu ZhuDepartments of Surgery and Pathology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58202, USA.
Wenyi Qin
Ke Zhang
George E Rottinghaus
Yin-Chieh Chen
Beth Kliethermes
Edward R Sauter
University of North Dakota · USUniversity of Missouri · US

Funding

Epigenetic Effects of ResveratrolR21CA124818 · NCI · UNIVERSITY OF NORTH DAKOTA · PI SAUTER, EDWARD R · 2007 to 2008
$314k
NCI NIH HHS CA124818NCI NIH HHS R21 CA124818
6 · The paper itself

Abstract

Trans-resveratrol, present in high concentration in the skin of red grapes and red wine, has a dose-dependent antiproliferative effect in vitro, prevents the formation of mammary tumors, and has been touted as a chemopreventive agent. Based upon in vitro studies demonstrating that trans-resveratrol downregulates the expression of 1) DNA methyltransferases and 2) the cancer promoting prostaglandin (PG)E(2), we determined if trans-resveratrol had a dose-related effect on DNA methylation and prostaglandin expression in humans. Thirty-nine adult women at increased breast cancer risk were randomized in double-blind fashion to placebo, 5 or 50 mg trans-resveratrol twice daily for 12 wk. Methylation assessment of 4 cancer-related genes (p16, RASSF-1α, APC, CCND2) was performed on mammary ductoscopy specimens. The predominant resveratrol species in serum was the glucuronide metabolite. Total trans-resveratrol and glucuronide metabolite serum levels increased after consuming both trans-resveratrol doses (P < .001 for both). RASSF-1α methylation decreased with increasing levels of serum trans-resveratrol (P = .047). The change in RASSF-1α methylation was directly related to the change in PGE(2) (P = .045). This work provides novel insights into the effects of trans-resveratrol on the breast of women at increased breast cancer risk, including a decrease in methylation of the tumor suppressor gene RASSF-1α. Because of the limited sample size, our findings should be validated in a larger study.

Indexed as

Promoter Regions, GeneticBreastBreast NeoplasmsCyclin D2DinoprostoneDNA MethylationDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMiddle AgedResveratrolRisk FactorsStilbenesTumor Suppressor ProteinsCCND2 protein, humanCyclin D2DinoprostoneRASSF1 protein, humanResveratrolStilbenesTumor Suppressor Proteins

Identifiers

PMID22332908
PMCPMC3392022
OpenAlexW1971943164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.